Aligos Therapeutics Presents Positive Data at the Conference on Retroviruses and Opportunistic Infections (CROI)

Rhea-AI Summary

Aligos Therapeutics (Nasdaq: ALGS) reported positive clinical data presented at CROI (Feb 22–25, 2026) from two posters: a Phase 1 monotherapy study of pevifoscorvir sodium showing high viral suppression in chronic HBV, and pharmacokinetics data for ALG-097558 in hepatic and renal impairment.

The ALG-097558 work acknowledges partial federal funding under Contract No. 75N93023C00052 and presentations were scheduled Feb 23 and Feb 25, 2026 in Denver.

Argus Feb 23 session

+2.06% close to close Open Argus

Details

News Market Reaction – ALGS

On Feb 23, the day this news came out, ALGS closed 2.06% above the previous close.

Data tracked by StockTitan Argus for the Feb 23 session.

Key Figures

CROI dates: February 22–25, 2026 Pevifoscorvir poster: Poster #588 ALG-097558 poster: Poster #737 +1 more

CROI dates

February 22–25, 2026

Conference on Retroviruses and Opportunistic Infections schedule

Pevifoscorvir poster

Poster #588

Phase 1 monotherapy study in chronic HBV at CROI

ALG-097558 poster

Poster #737

Renal and hepatic impairment pharmacokinetics study at CROI

Government contract

Contract No. 75N93023C00052

NIAID/NIH/HHS funding identifier for ALG-097558 project

Historical Context

5 past events · Latest: Jan 30

5 events

1. Jan 30

   Inducement equity grants

   24h Move

   -0.6%

   Inducement stock options for 81,100 shares granted to new employees.

2. Jan 21

   Phase 2 study update

   24h Move

   -0.1%

   B-SUPREME Phase 2 pevifoscorvir update with interim analyses timing and CMO change.

3. Jan 13

   CCO appointment

   24h Move

   +6.1%

   Appointment of Chief Commercial Officer to build global commercial capabilities.

4. Dec 12

   Inducement equity grants

   24h Move

   +15.5%

   Non-qualified options for 14,100 shares granted under 2024 Inducement Plan.

5. Dec 11

   Positive trial data

   24h Move

   +1.6%

   Positive HEP-DART 2025 data for pevifoscorvir and obesity combo candidate ALG-055009.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

monotherapy, chronic hepatitis B virus, hepatic impairment, renal impairment, +3 more

7 terms

monotherapy medical

"highlights the Phase 1 monotherapy study of pevifoscorvir sodium"

Monotherapy is a treatment approach that uses only one type of medicine or therapy to address a condition, instead of combining multiple options. For investors, understanding monotherapy matters because it can influence a company's development strategy, risk profile, and potential market size, especially if the single-treatment approach proves effective or faces limitations compared to combination therapies.

chronic hepatitis B virus medical

"under development for the treatment of chronic hepatitis B virus (HBV) infection"

Chronic hepatitis B virus is a long‑term infection of the liver caused by the hepatitis B virus that persists for months or years and can gradually damage liver tissue. For investors it matters because chronic infections create sustained markets for diagnostics, treatments and vaccines, influence healthcare costs and regulatory review, and can affect the commercial prospects or risk profile of companies developing therapies—like a smoldering fire that needs ongoing management rather than a one‑time fix.

hepatic impairment medical

"ALG-097558 presentation showcases data from participants with hepatic and renal impairment"

Hepatic impairment means the liver is not working normally, which changes how the body breaks down and clears medicines and other substances. For investors, this matters because weakened liver function can force dose changes, limit which patients can use a drug, or raise safety concerns—similar to a factory running slower and producing fewer usable products—affecting regulatory approval, market size, and sales forecasts.

renal impairment medical

"ALG-097558 presentation showcases data from participants with hepatic and renal impairment"

Renal impairment means the kidneys are not working as well as they should to filter blood and remove waste, like a home water filter that’s become clogged and slows flow. For investors, it matters because reduced kidney function can change how drugs are dosed, who can take them, and the size and safety profile of a treatment’s market, which can affect regulatory decisions, sales forecasts, and company risk.

pan-coronavirus medical

"ritonavir-free small molecule pan-coronavirus protease inhibitor"

Pan-coronavirus describes medicines, vaccines or diagnostic tools designed to work against a broad range of coronaviruses and their variants by targeting features those viruses share. For investors, a pan-coronavirus product is like a universal charger: one solution can serve many future outbreaks and strains, which can expand the potential market, reduce the risk that a single new variant will make the product obsolete, and therefore affect a developer’s long-term revenue and valuation.

protease inhibitor medical

"ritonavir-free small molecule pan-coronavirus protease inhibitor"

A protease inhibitor is a medicine that blocks enzymes called proteases, which act like molecular scissors that cut proteins the body or viruses need to function. For investors, these drugs matter because successful protease inhibitors can become profitable treatments, influence a company’s drug pipeline value, face regulatory review and patent timelines, and carry risks such as side effects or resistance that affect sales and company valuation.

pharmacokinetics medical

"Title: Pharmacokinetics of ALG-097558, a Pan-Coronavirus 3CL-Pro Inhibitor"

Pharmacokinetics is the study of how a substance, such as a drug or chemical, moves through and is processed by the body over time. It tracks how it is absorbed, distributed, broken down, and eventually eliminated. For investors, understanding pharmacokinetics helps gauge the effectiveness, safety, and potential risks of new medications or treatments, which can influence a company’s success and valuation in the healthcare industry.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced positive data from two presentations at the Conference on Retroviruses and Opportunistic Infections (CROI), being held February 22 – 25, 2026 in Denver, Colorado.

The pevifoscorvir sodium presentation highlights the Phase 1 monotherapy study of pevifoscorvir sodium, a potent CAM-E under development for the treatment of chronic hepatitis B virus (HBV) infection. Additionally, the ALG-097558 presentation showcases data from participants with hepatic and renal impairment. The ALG-097558 project has been funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services (HHS), under Contract No. 75N93023C00052.

“We are pleased to continue showcasing the best/first-in-class pevifoscorvir sodium data from the Phase 1 study in participants with chronic HBV infection,” said Lawrence Blatt, Ph.D., M.B.A., Chairman, President, and CEO of Aligos Therapeutics. “Additionally, we continue to move our COVID program forward with grants from government agencies and are pleased to show some of this important clinical work at CROI this year.”

Details of the presentations are as follows:

Pevifoscorvir sodium: Potential first-/best-in-class small molecule CAM-E under investigation for chronic hepatitis B virus (HBV) infection 

Poster #: 588
Title: High Viral Suppression in Chronic HBV Infection Subjects with Pevifoscorvir Sodium Monotherapy
Presenter: Stanley Wang, MD
Date/Time: February 23, 2026, 2:30pm – 4:00pm MST
Session: Beyond the C: Hepatitis D, B, and E

ALG-097558: Potential best-in-class ritonavir-free small molecule pan-coronavirus protease inhibitor

Poster #: 737
Title: Pharmacokinetics of ALG-097558, a Pan-Coronavirus 3CL-Pro Inhibitor, in Renal and Hepatic Impairment
Presenter: Megan Fitzgerald, PhD
Date/Time: February 25, 2026, 2:30pm – 4:00pm MST
Session: SARS-CoV-2 Therapy, Consequences, and Outcomes

The presentations can be found on the Posters & Presentations section of the Aligos website (www.aligos.com) after the live event.

About Aligos

Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biotechnology company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&D expertise to advance its purpose-built pipeline of therapeutics for high unmet medical needs such as chronic hepatitis B virus (HBV) infection, obesity, metabolic dysfunction-associated steatohepatitis (MASH), and coronaviruses.

For more information, please visit www.aligos.com or follow us on LinkedIn or X.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements,” including without limitation, statements regarding Aligos’ financial results and performance as well as research and development activities, including regulatory status and the timing of announcements and updates relating to our regulatory filings and clinical trials. Such forward looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance, or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties inherent in the drug development process, including Aligos’ clinical-stage of development, the process of designing and conducting clinical trials, the regulatory approval processes, and other matters that could affect the sufficiency of Aligos’ capital resources to fund operations. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 6, 2025 and its future periodic reports to be filed or submitted with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.

Investor Contact
Aligos Therapeutics, Inc.
Jordyn Tarazi
Vice President, Investor Relations & Corporate Communications
+1 (650) 910-0427
jtarazi@aligos.com

Media Contact
Inizio Evoke
Jake Robison
Vice President
Jake.Robison@inizioevoke.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What data did Aligos (ALGS) present about pevifoscorvir sodium at CROI on Feb 23, 2026?

The poster reported high viral suppression with pevifoscorvir sodium monotherapy in Phase 1 chronic HBV subjects. According to the company, the presentation highlighted potent CAM-E activity and safety findings from the Phase 1 monotherapy cohort at CROI 2026.

What was the focus of Aligos's (ALGS) ALG-097558 presentation at CROI on Feb 25, 2026?

The presentation detailed pharmacokinetics in renal and hepatic impairment for ALG-097558, a pan-coronavirus protease inhibitor. According to the company, the poster examined PK changes and dosing considerations in impaired hepatic and renal function.

How are the CROI 2026 presentations timed for Aligos (ALGS) investors and researchers?

Aligos scheduled pevifoscorvir on Feb 23 and ALG-097558 on Feb 25 during CROI 2026 in Denver. According to the company, both posters were presented in afternoon sessions for scientific and clinical audiences.

Does Aligos (ALGS) disclose funding for the ALG-097558 project at CROI 2026?

Yes, the company disclosed federal funding under Contract No. 75N93023C00052 from NIAID/NIH/HHS. According to the company, ALG-097558 development received whole or partial federal support for the reported work.

Where can investors find the full CROI 2026 posters from Aligos (ALGS)?

The posters are available after the live event in the Posters & Presentations section of Aligos's website. According to the company, full poster PDFs and presentation details will be posted on www.aligos.com post-conference.

What do the CROI 2026 results mean for Aligos's (ALGS) clinical programs in 2026?

The presentations provide early clinical and PK data supporting ongoing development of two programs in 2026. According to the company, these CROI updates advance clinical characterization but do not constitute late-stage efficacy proof.